Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
July 08, 2021 08:15 ET
|
Aileron Therapeutics, Inc.
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
July 01, 2021 08:00 ET
|
Aileron Therapeutics, Inc.
Phase 1b trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing chemotherapy with first-line carboplatin plus pemetrexedStudy will evaluate proportion of treatment cycles...
Aileron Therapeutics to be Added to the Russell Microcap® Index
June 24, 2021 07:00 ET
|
Aileron Therapeutics, Inc.
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
May 19, 2021 07:00 ET
|
Aileron Therapeutics, Inc.
-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D....
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 11, 2021 16:18 ET
|
Aileron Therapeutics, Inc.
Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out...
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 24, 2021 16:36 ET
|
Aileron Therapeutics, Inc.
2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective...
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:30 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate...
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
March 02, 2021 07:00 ET
|
Aileron Therapeutics, Inc.
-- Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed -- -- Trial anticipated to begin in...
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
January 11, 2021 06:30 ET
|
Aileron Therapeutics, Inc.
-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to...
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
January 06, 2021 09:30 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors...